Biopharmaceutical co AN2 Therapeutics jumps in Nasdaq debut

AN2 Therapeutics

25/03/2022 17:03

** Shares of biopharmaceutical co AN2 Therapeutics Inc
 ANTX.O  climb as high as 18.6% to $17.8 after stock market
debut
    ** Stock top pct gainer among Nasdaq-listed stocks
    ** ANTX opened at $16.85, 12.3% above its IPO price of $15
per share
    ** IPO was priced at the mid-point of co's target price
range of $14 to $16 per share
    ** Co sold 4.6 mln shares in an upsized IPO on Thursday,
raising about $69 mln 
    ** It was earlier looking to sell 4 mln shares 
    ** At the opening price, co fetched a market capitalization
of about $305.66 mln 
    ** ANTX develops treatments for rare, chronic and infectious
diseases with unmet needs
    ** Its initial product candidate is a once-daily oral
treatment for patients with chronic NTM lung disease

 (Reporting by Sohini Podder in Bengaluru)
 ((sohini.podder@thomsonreuters.com))